MedTrace Logo

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-04-14

No results posted yet for this study

Summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Conditions

Interventions

DRUG

Avelumab

oral

DRUG

Lorlatanib

oral

DRUG

Talazoparib

oral

DRUG

Pemetrexed

IV (intravenous) infusion

DRUG

Axitinib

oral

DRUG

CMP 001

IT (intratumoral) or SC (subcutaneous)

DRUG

Utomilumab

IV infusion

DRUG

PF04518600

IV infusion

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-29
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Denmark
  • France
  • Hungary
  • Israel
  • Italy
  • Japan
  • Mexico
  • New Zealand
  • Poland
  • Russia
  • Serbia
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05059522 on ClinicalTrials.gov